LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Danish J. Qureshi Sells 150,000 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) insider Danish J. Qureshi sold 150,000 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $5.21, for a total value of $781,500.00. Following the completion of the transaction, the insider now owns 439,002 shares of the company’s stock, valued at approximately $2,287,200.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST opened at $5.29 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average is $6.17 and its two-hundred day moving average is $6.58. LifeStance Health Group, Inc. has a 12 month low of $4.74 and a 12 month high of $9.59.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. The company had revenue of $300.44 million for the quarter, compared to the consensus estimate of $299.02 million. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The company’s revenue for the quarter was up 18.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.09) EPS. On average, analysts predict that LifeStance Health Group, Inc. will post -0.26 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on LFST. Morgan Stanley reiterated an “overweight” rating and issued a $10.00 price target on shares of LifeStance Health Group in a research report on Monday, April 22nd. The Goldman Sachs Group raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Monday, March 4th. Barclays raised their price objective on LifeStance Health Group from $7.00 to $8.00 and gave the stock an “underweight” rating in a research report on Thursday, February 29th. Finally, Jefferies Financial Group raised their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $8.80.

Institutional Trading of LifeStance Health Group

A number of institutional investors and hedge funds have recently modified their holdings of LFST. DekaBank Deutsche Girozentrale bought a new stake in shares of LifeStance Health Group during the third quarter valued at approximately $34,000. Sunbelt Securities Inc. acquired a new stake in LifeStance Health Group in the 3rd quarter valued at $34,000. Bessemer Group Inc. boosted its stake in LifeStance Health Group by 43.4% in the 1st quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock valued at $56,000 after buying an additional 2,768 shares in the last quarter. Allen Investment Management LLC acquired a new stake in LifeStance Health Group in the 1st quarter valued at $79,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in LifeStance Health Group in the 4th quarter valued at $93,000. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.